Topic: An international, expert-led consensus initiative to develop systematic, evidence-based recommendations for the treatment of noninfectious uveitis in the era of biologics. Clinical Relevance: The availability of biologic agents for the treatment of human eye disease has altered practice patterns for the management of noninfectious uveitis. Current guidelines are insufficient to assure optimal use of noncorticosteroid systemic immunomodulatory agents. Methods: An international expert steering committee comprising 9 uveitis specialists (including both ophthalmologists and rheumatologists) identified clinical questions and, together with 6 bibliographic fellows trained in uveitis, conducted a Preferred Reporting Items for Systematic Reviews and Meta-Analyses protocol systematic reviewof the literature (English language studies from January 1996 through June 2016; Medline [OVID], the Central Cochrane library, EMBASE,CINAHL,SCOPUS,BIOSIS, andWeb of Science). Publications included randomized controlled trials, prospective and retrospective studies with sufficient follow-up, case series with 15 cases or more, peer-reviewed articles, and hand-searched conference abstracts from key conferences. The proposed statements were circulated among 130 international uveitis experts for review.Atotal of 44 globally representativegroupmembersmet in late 2016 to refine these guidelines using a modified Delphi technique and assigned Oxford levels of evidence. Results: In total, 10 questions were addressed resulting in 21 evidence-based guidance statements covering the following topics: when to start noncorticosteroid immunomodulatory therapy, including both biologic and nonbiologic agents; what data to collect before treatment; when to modify or withdraw treatment; how to select agents based on individual efficacy and safety profiles; and evidence in specific uveitic conditions. Shared decision-making, communication among providers and safety monitoring also were addressed as part of the recommendations. Pharmacoeconomic considerations were not addressed. Conclusions: Consensus guidelines were developed based on published literature, expert opinion, and practical experience to bridge the gap between clinical needs and medical evidence to support the treatment of patients with noninfectious uveitis with noncorticosteroid immunomodulatory agents.

Guidance on noncorticosteroid systemic immunomodulatory therapy in noninfectious uveitis: fundamentals of care for uveitis (focus) initiative / Dick, Andrew D.; FMedSci, ; Correspondence information about the author FMedSci, FRCOphth; Dick†, FRCOphth Andrew D.; the author FMedSci, Email; Dick, FRCOphth Andrew D.; Rosenbaum, James T.; MD†, ; Al-Dhibi, Hassan A.; MD, ; Jr., Rubens Belfort; PhD, MD; Brézin, Antoine P.; PhD, MD; Phaik Chee, Soon; FRCS, FRCOphth; Davis, Janet L.; MA, MD; Ramanan, Athimalaipet V.; FRCPCH, FRCP; Sonoda, Koh-Hei; PhD, MD; Carreño, Ester; PhD, MD; Nascimento, Heloisa; MD, ; Salah, Sawsen; MD, ; Salek, Sherveen; MD, ; Siak, Jay; FRCSEd(Ophth), FRCOphth; Steeples, Laura; FRCOphth, ; Massimo Accorinti, MBChB(Hons); Acharya, Nisha; Adan, Alfredo; Agrawal, Rupesh; Akkoc, Nurullah; Al Ghamdi, Saed; Al Ghamdi, Turki; Al Saati, Anood; Alsabaani, Nasser; Al-Shamarani, Mohamed; Bachta, Artur; Barisani-Asenbauer, Talin; Beare, Nicholas; Belga Ottoni Porto, Fernanda; Blanco, Ricardo; Chan Sook Yee, Anita; Chandran, Vinod; Chiquet, Christophe; Hee Chng, Hiok; Cimbalas, Andrius; Cimino, Luca; Cordero-Coma, Miguel; Cristobal, Couto; Cuevas, Miguel; Eurico da Fonseca, João; de Boer, Joke; de la Torre, Alejandra; De Schryver, Ilse; Derzko-Dzulynsky, Larissa; Diaz-Valle, David; Eugenia Duran Merino, Claudia; Facsko, Andrea; Figueira, Luis; Fonollosa, Alejandro; Fortin, Eric; Gale, Richard; Galeazzi, Mauro; Garcia, Sandra; Maria Garcia Ruiz de Morales, Jose; Gašperšič, Nataša; Goldstein, Debra; Guedes, Marta; Guex-Crosier, Yan; Gul, Ahmet; Hamam, Rola; Haroon, Muhammad; Hasegawa, Kenichi; Heiligenhaus, Arnd; Hooper, Claire; Hwang, Yih-Shiou; Hwang, De-Kuang; Juanola, Xavier; Kaburaki, Toshikatsu; Kadayifcilar, Sibel; Kempen, John; Kezuka, Takeshi; Kherani, Amin; Kirsimäe, Maarja; Kotaniemi, Kaisu; Kraut, Aleksandra; Kubicka-Trząska, Agnieszka; Kuffova, Lucia; Lightman, Susan; Lim, Lyndell; Kiak Lim, Wee; McCluskey, Peter; McGuire, Mairide; Mirabelli, Pierfrancesco; Miserocchi, Elisabetta; Misiuk-Hojło, Marta; Muccioli, Cristina; Muñoz, Santiago; Murphy, Conor; Murray, Philip I.; Nagy, Zoltan; Namba, Kenichi; Neri, Piergiorgio; Nguyen, Quan; O'Gradaigh, Donncha; Omair, Mohammed; Otsa, Kati; Ozyazgan, Yilmaz; Pablo, Franco; PAROLI, Maria Pia; Pleyer, Uwe; Poór, Gyula; Proença, Rui; Rabinovitch, Theodore; Read, Russell; Rebrov, Margarita; Recillas-Gispert, Claudia; Rothova, Aniki; Schwartzman, Sergio; Seve, Pascal; Sharma, Srilakshmi; Sims, Joanne; Sohár, Nicolette; Suhler, Eric; Szántó, Sándor; Szepessy, Zsuzsanna; Tappeiner, Christoph; Thorne, Jennifer; Tugal Tutkun, Ilknur; Turno-Kręcicka, Anna; Van Calster, Joachim; van der Horst-Bruinsma, Irene; Vidovič Valentinčič, Nataša; Vitale, Albert; Voorduin Ramos, Stephanie; Vukojevic, Nenad; Wakefield, Denis; Willermain, François; Yalcindag, Nilufer; Hisae Yamamoto, Joyce; Yeh, Stephen; Zemaitiene, Reda; Ziouzina, Olga. - In: OPHTHALMOLOGY. - ISSN 0161-6420. - 125:5(2018), pp. 757-773. [10.1016/j.ophtha.2017.11.017]

Guidance on noncorticosteroid systemic immunomodulatory therapy in noninfectious uveitis: fundamentals of care for uveitis (focus) initiative

Maria Pia Paroli
Membro del Collaboration Group
;
2018

Abstract

Topic: An international, expert-led consensus initiative to develop systematic, evidence-based recommendations for the treatment of noninfectious uveitis in the era of biologics. Clinical Relevance: The availability of biologic agents for the treatment of human eye disease has altered practice patterns for the management of noninfectious uveitis. Current guidelines are insufficient to assure optimal use of noncorticosteroid systemic immunomodulatory agents. Methods: An international expert steering committee comprising 9 uveitis specialists (including both ophthalmologists and rheumatologists) identified clinical questions and, together with 6 bibliographic fellows trained in uveitis, conducted a Preferred Reporting Items for Systematic Reviews and Meta-Analyses protocol systematic reviewof the literature (English language studies from January 1996 through June 2016; Medline [OVID], the Central Cochrane library, EMBASE,CINAHL,SCOPUS,BIOSIS, andWeb of Science). Publications included randomized controlled trials, prospective and retrospective studies with sufficient follow-up, case series with 15 cases or more, peer-reviewed articles, and hand-searched conference abstracts from key conferences. The proposed statements were circulated among 130 international uveitis experts for review.Atotal of 44 globally representativegroupmembersmet in late 2016 to refine these guidelines using a modified Delphi technique and assigned Oxford levels of evidence. Results: In total, 10 questions were addressed resulting in 21 evidence-based guidance statements covering the following topics: when to start noncorticosteroid immunomodulatory therapy, including both biologic and nonbiologic agents; what data to collect before treatment; when to modify or withdraw treatment; how to select agents based on individual efficacy and safety profiles; and evidence in specific uveitic conditions. Shared decision-making, communication among providers and safety monitoring also were addressed as part of the recommendations. Pharmacoeconomic considerations were not addressed. Conclusions: Consensus guidelines were developed based on published literature, expert opinion, and practical experience to bridge the gap between clinical needs and medical evidence to support the treatment of patients with noninfectious uveitis with noncorticosteroid immunomodulatory agents.
File allegati a questo prodotto
File Dimensione Formato  
Dick_Giudance_2018.pdf

accesso aperto

Note: https://www.aaojournal.org/article/S0161-6420(17)32446-6/abstract
Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 362.98 kB
Formato Adobe PDF
362.98 kB Adobe PDF Visualizza/Apri PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11573/1209455
Citazioni
  • ???jsp.display-item.citation.pmc??? 43
  • Scopus 106
  • ???jsp.display-item.citation.isi??? 99
social impact